Estland - estisk - Ravimiamet

krka, d.d., novo mesto - sunitiniib - kõvakapsel - 25mg 14tk; 25mg 10tk; 25mg 7tk; 25mg 20tk; 25mg 21tk; 25mg 28tk

Estland - estisk - Ravimiamet

krka, d.d., novo mesto - sunitiniib - kõvakapsel - 12,5mg 14tk; 12,5mg 30tk; 12,5mg 21tk; 12,5mg 7tk; 12,5mg 28tk; 12,5mg 10tk; 12,5mg 20tk

Estland - estisk - Ravimiamet

krka, d.d., novo mesto - sunitiniib - kõvakapsel - 50mg 21tk; 50mg 10tk; 50mg 14tk; 50mg 20tk; 50mg 7tk; 50mg 28tk

Estland - estisk - Ravimiamet

norameda uab - sunitiniib - kõvakapsel - 50mg 28tk; 50mg 30tk

Den Europæiske Union - estisk - EMA (European Medicines Agency)

mylan ireland limited - rivaroksabaan - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombootilised ained - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Estland - estisk - Ravimiamet

stada arzneimittel ag - sunitiniib - kõvakapsel - 37,5mg 30tk; 37,5mg 28tk

Estland - estisk - Ravimiamet

stada arzneimittel ag - sunitiniib - kõvakapsel - 50mg 30tk; 50mg 28tk

Estland - estisk - Ravimiamet

stada arzneimittel ag - sunitiniib - kõvakapsel - 12,5mg 30tk

Estland - estisk - Ravimiamet

stada arzneimittel ag - sunitiniib - kõvakapsel - 25mg 28tk; 25mg 30tk

Estland - estisk - Ravimiamet

viasana uab - sunitiniib - kõvakapsel - 25mg 30tk